Sweden-based Bonesupport has announced that the Centre Hospitalier Universitaire Vaudois (CHUV) in Switzerland has initiated the Cerament |G Bone Healing study, designed to investigate absorption and bone in-growth of Cerament|G in one-stage surgical revisions of infections.
The Cerament|G Bone Healing study will follow patients for one-year post surgery. CT verified Cerament|G absorption and new bone in-growth are primary endpoints of the study.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Secondary and safety endpoints of the study are bone healing, post-operative infections and serum levels of gentamicin.
CHUV septic unit head and principal clinical investigator for the Cerament|G Bone Healing study Dr Olivier Borens said: “We believe the use of Cerament|G will be of advantage for the patient when bone healing can be achieved with a one-stage procedure instead of a two-stage procedure, thus decreasing potential surgery-related complications.”
Bonesupport chief medical officer Dr Mogens Gisselbaeck said: “We expect the results of this study will further qualify the positive outcomes reported from the Oxford Cerament|G study, and that mounting Cerament|G data may impact the surgical strategy related to the management of bone infections.”
Cerament |G is an injectable antibiotic eluting ceramic bone graft substitute indicated to promote and protect bone healing in the management of osteomyelitis (bone infections).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCerament |G obtained received CE Mark approval and is currently available in select markets. Currently, it is not available in the US.
